Navigation Links
PDL BioPharma to Present at Two Upcoming Investor Conferences
Date:2/20/2013

INCLINE VILLAGE, Nev., Feb. 20, 2013  /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming conferences.

RBC Capital Markets Healthcare Conference
Wednesday, February 27, 2013
9:00 a.m. ET
New York City

Cowen and Company 33rd Annual Healthcare Conference
Wednesday, March 6, 2013
9:20 a.m. ET
Boston, MA

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

To access the live and subsequently archived webcasts of the presentations, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. The archived webcast will be available for seven days following each presentation.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
2. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
3. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
4. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
5. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
6. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
7. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
8. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
9. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
10. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
11. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
(Date:10/5/2017)... ... October 05, 2017 , ... NIH ... of its Nanobind DNA/RNA extraction technology . Nanobind is a novel magnetic ... surface and that can be used for a wide variety of sample preparation ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):